Compare INSG & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSG | CRDF |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.9M | 86.8M |
| IPO Year | 2000 | 2012 |
| Metric | INSG | CRDF |
|---|---|---|
| Price | $4.31 | $0.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $15.33 | $9.63 |
| AVG Volume (30 Days) | 441.7K | ★ 799.1K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $313,832,000.00 | $365,993.00 |
| Revenue This Year | $16.21 | N/A |
| Revenue Next Year | $13.28 | N/A |
| P/E Ratio | $30.92 | ★ N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $3.96 | $0.76 |
| 52 Week High | $21.90 | $3.31 |
| Indicator | INSG | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 24.49 | 41.71 |
| Support Level | N/A | $0.76 |
| Resistance Level | $12.95 | $1.13 |
| Average True Range (ATR) | 0.43 | 0.07 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 5.87 | 17.72 |
Inseego Corp is involved in the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things, and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by application software and cloud services designed to enable customers to analyze data insights and configure and manage their hardware easily. It generates maximum revenue from the United States and Canada. The company also has a presence in Europe (including the United Kingdom).
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.